Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (DE:4XC1)
FRANKFURT:4XC1
4XC1 Stock Chart & Stats
€13.30
€0.15(1.85%)
At close: 4:00 PM EST
€13.30
€0.15(1.85%)
Day’s Range― - ―
52-Week Range€9.00 - €14.50
Previous CloseN/A
Volume0.00
Average Volume (3M)17.00
Market Cap
€664.19M
Enterprise Value€706.24M
Total Cash (Recent Filing)€309.16M
Total Debt (Recent Filing)€149.59M
Price to Earnings (P/E)―
Beta0.46
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding50,546,290
10 Day Avg. Volume52
30 Day Avg. Volume17
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)7.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€29.66Price Target Upside123.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Launch PerformanceAnalyst highlights that initial Ekterly sales materially exceeded consensus and start forms surpassed physician expectations, indicating stronger-than-anticipated market reception that could lift revenue forecasts.
Payer Access And CoverageAnalyst points to favorable commentary from major insurers and broader formulary coverage prospects that should enable patient access to an on-demand HAE therapy and expand the addressable market.
Physician Adoption And Patient PersistenceAnalyst observes a growing number of unique prescribers alongside high refill rates, suggesting increasing prescriber comfort and patient persistence that may support sustained demand.
Bears Say
Demand Sustainability And Adoption BreadthAnalyst notes sales appear driven more by refills than new patient starts and expresses uncertainty that adoption will broaden beyond core HAE physicians given potential payer quantity limits and access constraints.
Patient Mix RiskAnalyst cautions that early use is concentrated among patients with heavier disease burden, so average refill frequency could moderate as milder patients adopt the therapy, potentially slowing consumption growth.
Revenue VisibilityAnalyst warns that limited disclosure of inventory levels and payer performance metrics reduces visibility into organic sales and clouds near-term revenue clarity.
KalVista Pharmaceuticals News
4XC1 FAQ
What was KalVista Pharmaceuticals’s price range in the past 12 months?
KalVista Pharmaceuticals lowest stock price was €9.00 and its highest was €14.50 in the past 12 months.
What is KalVista Pharmaceuticals’s market cap?
KalVista Pharmaceuticals’s market cap is €664.19M.
When is KalVista Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were KalVista Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is KalVista Pharmaceuticals overvalued?
According to Wall Street analysts KalVista Pharmaceuticals’s price is currently Undervalued.
Does KalVista Pharmaceuticals pay dividends?
KalVista Pharmaceuticals does not currently pay dividends.
What is KalVista Pharmaceuticals’s EPS estimate?
KalVista Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KalVista Pharmaceuticals have?
KalVista Pharmaceuticals has 50,546,290 shares outstanding.
What happened to KalVista Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of KalVista Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:4XC1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
KalVista Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€29.66 (123.03% Upside)
€29.66 (123.03% Upside)
Blogger Sentiment
Neutral
DE:4XC1 Sentiment 50%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
71.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.17%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
4XC1 Earnings Call
Q3 2025
0:00 / 0:00
4XC1 Stock 12 Month Forecast
Average Price Target
€29.66
▲(123.03% Upside)
Technical Analysis
Savara
―
Arvinas Holding Company
―
Gossamer Bio
―
Compass Therapeutics
―
Bicara Therapeutics Inc.
―